Cardioprotective Role of Estrogen in Takotsubo Cardiomyopathy

Ahsan Waqar 1, Ashish Jain 2, Christine Joseph 3, Kosha Srivastava 4, Olive Ochuba 2, Tasnim Alkayyali 5, Sujan Poudel 6

1. Family Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA 2. Internal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA 3. Urology and Obstetrics & Gynecology, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA 4. Neurology, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA 5. Pathology, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA 6. Psychiatry and Behavioral Sciences, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA 7. Division of Research & Academic Affairs, Larkin Community Hospital, South Miami, USA

Received 10/16/2021
Review began 01/24/2022
Review ended 03/02/2022
Published 03/04/2022
© Copyright 2022 Waqar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Takotsubo cardiomyopathy (TC) is a rare, reversible cause of left ventricular wall motion abnormality (LVWMA) that mimics the presentation of acute myocardial infarction (AMI). TC is usually preceded by an emotional or physical stressor and appears to be more common in postmenopausal women. Various pathophysiological hypotheses of TC have been proposed, but the exact mechanism of action remains elusive. Elevated levels of catecholamines leading to cardiac dysfunction are the most prevalent hypothesis. The protective role of estrogen in the development of cardiomyopathies has been studied extensively. International Takotsubo Diagnostic Criteria (InterTAK) and Mayo clinic diagnostic criteria both have the stipulation stating prevalence of TC is higher in postmenopausal women which hints towards the protective role of estrogen in the development of TC. To review the protective role of estrogen in the mechanism of this novel pathology, we searched PubMed and Google Scholar for the relevant articles by using keywords such as: "takotsubo cardiomyopathy", "apical ballooning", "broken heart syndrome", "stress cardiomyopathy", "left ventricle wall motion abnormality", "estrogen", "estradiol" and "sex hormones". Our research revealed that although the prevalence of TC is greater in postmenopausal women as compared to men, the prognosis is worse in men. It also revealed the involvement of multiple cellular pathways under the influence of estrogen that could explain the cardioprotective effect of estrogen. Most of the articles found were based on animal studies, thus, there is an emphasis on future human studies. However, we strongly suggest evaluating estrogen levels as part of the initial workup for any patient presenting with signs and symptoms of cardiac pathology.

Categories: Cardiology, Family/General Practice, Internal Medicine
Keywords: sex hormones, estradiol, estrogen, left ventricle wall motion abnormality, stress cardiomyopathy, broken heart syndrome, apical ballooning, takotsubo cardiomyopathy

Introduction And Background

Epidemiology

The prevalence of takotsubo cardiomyopathy (TC) is 1%-2% in patients presenting with symptoms of acute coronary syndrome (ACS) [1]. Brinjikji et al. (2012) studied the in-hospital mortality rate among patients with TC. The study included a sample of 24,701 patients from the National Inpatient Database Samples between 2008-2009 and revealed a mortality rate of 4.2% in patients presenting with TC. Stratifying the study by gender revealed that 89% of patients with TC were females, with a higher mortality rate in men as compared to women (8.4% vs 3.6%) [2]. Another cohort study by Stermaier et al. (2016) studied the long-term mortality rate of patients with TC in comparison to the mortality rate of patients with ST-elevation myocardial infarction (STEMI). After studying a total of 286 patients, the long-term mortality rate was found to be worse in patients with TC as compared to patients with STEMI (24.7% versus 15.1%, hazard ratio (HR) 1.58, 95% confidence interval (CI) 1.07-2.33) [3]. Because of the apparent cardioprotective role of estrogen on cardiomyopathies, it is of great importance to have a thorough understanding of the underlying pathophysiology of this novel disease along with the cellular changes that occur under the influence of estrogen.

Background

TC is a rare disease that has recently started to gain recognition. TC was first described by Satoh (1990) in Japan who derived the name of the pathology from the shape of the container which is used to catch octopus (tako=octopus, tsubo=pot) [4]. The shape of the container is rounded at the bottom with a thin neck, representing the shape of the left ventricle in TC [4-5]. Another name of the disease is "apical ballooning", which represents the shape of the left ventricle during systole. Although apical ballooning of the left ventricle is the most common finding in TC, other left ventricle wall motion abnormalities (LVWMA) can...
also be found at the midapical, midventricular, midbasal, and basal regions. The presentation of TC is similar to someone experiencing acute myocardial infarction (AMI), such that the patient presents with chest pain, palpitations, hypertension, light-headedness, and elevated troponin I. However, unlike AMI, patients with TC do not have coronary artery disease (CAD) and the disease is reversible [4-5]. Figure 1 below shows the shape of the octopus catcher and the shape of the left ventricle under stress, thus, the name takotsubo-cardiomyopathy.

![FIGURE 1: Pictorial representation of octopus catcher vs apical ballooning of left ventricle](image)

Modified picture representing the shape of octopus catcher (left) compared to the apical ballooning of left ventricle under stress (right). Y-Hassan S, Tornvall P et al. [5]

The exact pathophysiology of TC is unknown. The most widely accepted hypothesis is the elevated level of catecholamines is preceded by an emotional or physical trigger, as presented by Wittstein et al. (2005) [6]. The study evaluated 19 patients with left ventricle dysfunction after emotional stress, and 13 patients showed elevated levels of catecholamines. The study also observed complete resolution of left ventricular dysfunction. Furthermore, the histopathological analysis of TC myocardium showed contraction band necrosis, in contrast to coagulation necrosis seen in myocardial infarction (MI) [6].

Numerous diagnostic criteria have been proposed due to the novelty and complexity of the disease. In 2008, Mayo Clinic proposed a revised diagnostic criteria that had been widely used [7]. Ghadri et al. (2018) proposed the International Takotsubo Diagnostic Criteria (InterTAK criteria) [7]. According to the InterTAK criteria, patients display transient apical left ventricle ballooning, an emotional or physical stressor acting as a trigger, neurologic disorder including pheochromocytoma acting as a trigger, new ECG changes (ST-segment elevation, ST-segment depression, T-wave inversion, QTc prolongation), moderate elevation of cardiac biomarkers, having a CAD which is not a contraindication to TC, no evidence of infectious myocarditis, and being a postmenopausal woman [7].

The predominance of TC in postmenopausal women suggests the protective role of estrogen. It has been well established by Ostadal et al. (2014) that the incidence of ischemic heart disease (IHD) is lower in premenopausal women as compared to postmenopausal women [8]. Ostadal et al. (1984) conducted an observational study to gain insight into the impact of estrogen on the heart with oxygen deprivation. The study demonstrated that the male rat heart was less tolerable to oxygen deprivation than the female rat heart [9].

This review article aims to further explore the cardioprotective effect of estrogen. We aimed to reveal the changes that occur at the cellular level under the influence of estrogen and the estrogen-mediated effects through three kinds of estrogen receptors such as estrogen receptor-alpha (ER-α), estrogen receptor-beta (ER-β) and G-protein coupled estrogen receptor (GPER). In this review article, we searched Pumbed and Google scholar using the following keywords: "takotsubo cardiomyopathy", "apical ballooning", "stress cardiomyopathy", "broken-heart syndrome", "cardiomyopathy", "estrogen", "sex hormones" and "estradiol". Our search revealed 181 articles. After screening the title and abstract of each article from the year 2000 onwards, we included 20 articles that directly discussed the effects of estrogen and its receptors. In this review, we also discuss the impact of each type of ER individually and mention their protective effect against TC.

### Review

Estrogen is a sex hormone produced by the ovaries and is responsible for the development of secondary...
sexual characteristics in females. It has been well established that premenopausal women have a lower incidence of cardiac events as compared to men [10]. Also, the rate of IHD increases in postmenopausal women as compared to pre-menopausal women [8]. Estrogen exerts its physiological response by binding to its receptor, ER. Traditionally, two types of ER, ER-α and ER-β, were thought to mediate the response of estrogen. However, the third type of receptor, GPER, has also been found recently to play a significant role in the cardioprotective mechanism of estrogen.

A breakthrough study to mimic the presentation of TC in vivo was done by Ueyama et al. (2007) [11]. Their mouse model was ovariectomized (OVX) and treated with estrogen (OVX+E) to study the cellular response to immobilization (IMO) stress. After the induction of IMO, the heart rate was higher in OVX as compared to OVX+E. Furthermore, the study elucidated the involvement of sympathoadrenal pathways and found elevated levels of c-fos mRNA, a marker for cellular activation in OVX as compared to OVX+E. Also, they were successfully able to demonstrate the expression of both ER-α and ER-β receptors in estrogen-treated models which led to the increased expression of cardioprotective heat shock protein 70 (HSP 70) and atrial natriuretic peptide (ANP). Therefore, this study strongly suggests the cardioprotective role of estrogen and may help explain the increased incidence of TC in postmenopausal women as compared to pre-menopausal women [11].

To understand the association of estrogen and ischemic/reperfusion (I/R) injury, Booth et al. (2005) designed an experimental study where they studied the cardioprotective role of ER-α and ER-β on female rabbit hearts [12]. After pretreating the specimen with ER-agonists (PPT:ER-α and DPT:ER-β) for 30 minutes, they induced a 30-minute ischemic injury by occluding the left anterior descending artery followed by four hours of reperfusion and then measured the infarct size. They observed that the infarct area of ER-α receptors was of a smaller size as compared to ER-β receptors, indicating that the ER-α receptor might play a major role in the cardioprotective effect [12]. In another study, Pelzer et al. (2005) studied ER-β knockout in OVX mice [13]. They induced MI and found increased mortality in knockout mice as compared to wild type (WT) [13]. We can infer from these studies that ER-α is predominantly cardioprotective for AMI, whereas ER-β might play a role in lowering mortality.

The mitochondria play a vital role in the overall integrity of a cell. Mitochondrial connexin43 (Cx43) is crucial to cardiac myocyte recovery following I/R injury [14]. Wang et al. (2019) studied the response of estrogen (17β estradiol, E2) on the Cx43 using cardiomyocytes from a mouse model. Using immunoelectron microscopy and co-immunoprecipitation to determine the interaction of mitochondrial Cx43 with E2, myocardial function, and infarct size were measured. E2 with Cx43 improved the functional recovery of mitochondria and also improved the infarct size in female rats as compared to untreated rats [14].

To elaborate on the association of estrogen and congestive heart failure (CHF), Satoh et al. (2007) studied the estrogen-induced protection against CHF [15]. After eight weeks of estrogen treatment, they found the transgenic mice had improved contractility with decreased cardiac hypertrophy. Decreased apoptosis was observed with reduced Rac1 pathway activity along with increased thioredoxin and decreased thioredoxin reductase activity correlating with increased antioxidative properties of E2, thereby, providing further cardioprotection [15].

Zhang et al. (2018) studied the therapeutic properties of EXD (Er-Xian Decoction), commonly found in Chinese medicine to treat menopausal syndrome [16]. After 12 weeks of treatment with EXD, a substantial improvement in cardiac function was observed. The Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed expression of genes in the ventricle which could play a part in decreasing the expression of mRNA, myosin, and integrin, thereby helping with cardiac contractility [16].

The counterplay of estrogen and progesterone in relation to myocardial I/R insult was studied by Booth et al. (2007) [17]. Infarct size was measured after the hypoxic insult and revealed a significant small infarct size in estrogen-treated models as compared to OVX mice. In addition, the reversal of the observed cardioprotection was seen under the influence of progesterone [17].

Other studies done by Xu et al. (2004) and Luo et al. (2016) found estrogen-treated models to exhibit decreased expression of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and decreased production of reactive oxygen species (ROS) respectively [18,19], which further shines a light on the cardioprotective impact of estrogen. Table 7 summarizes the findings of all the above-mentioned studies.
| Author          | Year | Estrogen/Estrogen receptor | Model                  | Pathway/Markers studied | Findings                                | Summary                                      |
|-----------------|------|---------------------------|------------------------|-------------------------|-----------------------------------------|----------------------------------------------|
| Uyema et al.    | 2007 | ER-α and ER-β             | Ovariectomized mice    | c-fos mRNA              | E2→ ↑c-fos mRNA, ↑HSP70 and ↑ANP       | Estrogen provides cardioprotection via heat shock proteins |
| Booth et al.    | 2005 | E2, ER-α and ER-β         | Rabbit hearts          | Infarct size            | E2→ ↓infarct size                       | Estrogen is cardioprotective in ischemic injury |
| Pezzer et al.   | 2005 | ER-β                      | ER-β knockout          | mortality               | ER-β knockout → ↓mortality              | Estrogen could be beneficial in lowering mortality |
| Wang et al.     | 2019 | 17β estradiol, E2         | Cx43                   | Infarct size            | E2→ ↑Cx43→ ↑Mitochondrial stability → ↓infarct size | Estrogen plays a vital role in stability of mitochondrial integrity |
| Satoh et al.    | 2007 | 17-β Estradiol            | G α q transgenic mice  | Rac1/ Trx, Trx reductase| ↑Trx, ↑Rac1                              | Treatment with E2 improves CHF               |
| Zhang et al.    | 2016 | EXD                       | OVX                    | Myosin, integrin, mRNA  | ↓mRNA, ↓myosin, ↓integrin               | EXD is cardioprotective                      |
| Booth et al.    | 2007 | Estrogen & Progesterone   | New Zealand mice       | Infarct size            | ↓ Troponin I in Estrogen alone          | Cardioprotective effect of E2 reversed by medroxyprogesterone |
| Xu et al.       | 2004 | E2                       | Sprague-Dawley rat     | Estrogen + Superoxide dismutase mimic | ↓ expression of NADPH oxidase | Superoxide inhibition improves cardiac function |
| Luo et al.      | 2016 | E2                       | Neonatal rat cardiomyocyte | P38β, MnSOD       | ↓ROS                                    | E2 → P38β and MnSOD activation → ↓ROS        |

| TABLE 1: Cardioprotective role of estrogen receptors |
|-----------------------------------------------------|
| E2: estrogen or 17β-estradiol; EXD: Er-Xian Decoction; Trx: thioredoxin; MnSOD: manganese superoxide dismutase; OVX: ovariectomized rats; GPER: G-protein coupled estrogen receptor; ROS: reactive oxygen species; CHF: congestive heart failure; mRNA: messenger ribonucleic acid; NADPH: nicotinamide adenine dinucleotide phosphate; p38β: mitogen-activated protein kinase; c-fos mRNA: cell activation marker; HSP70: heat shock protein; ANP: atrial natriuretic peptide; Cx43: mitochondrial connexin43. |

**Estrogen receptor-α (E2-α or ER-α)**

In an experimental study to understand the cardioprotective effect of E2-α receptors, Xue B et al. (2007) studied the role of E2 in angiotensin II (ANG-II) induced hypertension [20]. After the administration of ANG-II, elevated blood pressures were observed in OVX and in estrogen receptor α knockout (ERαKO) mice. The mice were then administered estrogen which showed a significant decrease in blood pressure. This cardioprotective effect of estrogen was then reversed after the coadministration of nonselective estrogen antagonists, ICI 182, 780 [20].

Wang et al. (2006) studied the role of ER-α in MI [21]. MI causes the release of proinflammatory cytokines and increases the activation of the mitogen-activated protein kinase (MAPK) family and Jun N-terminal kinase (JNK) pathway which are markers for myocardial dysfunction [21]. Conversely, activation of the extracellular-signal-regulated kinase (ERK) pathway is consistent with cardiac function recovery [21]. Using enzyme-linked immunoassay (ELISA) and western blot techniques, ER-α may play a major role in MI [21].

Left ventricular outflow tract (LVOT) obstruction occurs in 15%-25% of TC patients leading to heart failure [22]. Westphal et al. (2012) studied the effect of E2, 16-α LE2 (selective E2-α agonist), and raloxifene on transverse aortic constriction (TAC) induced myocardial hypertrophy. After nine weeks, they observed reduced ejection fraction in all the groups, however, E2 and 16-α LE2 administered groups showed slowed progression of systolic dysfunction as compared to the raloxifene administered group, which showed the highest level of myocardial hypertrophy [23]. Also, E2 and 16-α LE2 groups showed decreased fibrosis [23]. Therefore, these studies shine a light on the cardioprotective role of ER-α which might be helpful in developing therapeutic drugs specific for alpha receptors. Table 2 summarizes the findings of the above-
mentioned studies.

| Author                | Year | Receptor | Pathway/Marker | Cardiovascular pathology | Findings                                                                 | Conclusion                                      |
|-----------------------|------|----------|----------------|--------------------------|---------------------------------------------------------------------------|-------------------------------------------------|
| Xue B et al. [20]     | 2007 | E2-α     | Blood pressure |                          | ANG-II→ ↑ BP in OVX WT and ERαKO E2→↓BP in OVX WT and ERαKO              | E2α is cardioprotective against hypertension     |
| Wang et al. [21]      | 2006 | E2-α     | MAPK and ERK   | Myocardial ischemia      | E2αKO → ↑MAPK, ↓ERK→ myocardial injury                                   | E2α is protective in myocardial ischemia         |
| Westphal et al. [23]  | 2012 | E2-α     | MH             |                          | E2 and 16-α LE2 → slowed progression of MH                                | Estrogen helps with myocardial hypertrophy       |

**TABLE 2: Cardioprotective role of estrogen receptor-α (E2-α)**

MAPK: mitogen-activated protein kinase; ERK: extracellular-signal-regulated kinase; MH: myocardial hypertrophy; ANG-II: angiotensin II; BP: blood pressure; OVX WT: ovariectomized wild type; ERαKO: estrogen receptor-α knockout; E2α: estrogen receptor-alpha; 16-α LE2: specific estrogen receptor-α agonist.

---

**Estrogen receptor-β (ER-β or E2-β)**

Multiple studies have been done to understand the cardioprotective role of ER-β. In one of the studies, Zhu et al. (2002) studied the effect of E2-β on hypertension [24]. In their study model, the vascular smooth muscles of ER-β deficient mice showed increased vasoconstriction and decreased production of inducible nitric oxide synthase (iNOS) as compared to the WT. Conversely, when treated with estrogen, E2-β deficient mice showed reduced vasoconstriction [24].

To further elucidate the role of E2-β on lowering blood pressure, Jazbutyte et al. (2008) treated the OVX mice with E2-β agonist (8ß-VE2) [25]. After 12 weeks of treatment, they found an enhanced expression of E2-β in the aorta with improved nitric oxide (NO)-induced vasodilation [25].

Moreover, I/R injury leads to mitochondrial instability by the activation of pro-apoptotic cytochrome c, which in turn causes the activation of caspase 9 [26]. Schubert et al. (2016) demonstrated the protective role of E2-β against mitochondrial instability [27]. They pre-treated the OVX mice with either E2 or ER-β specific agonist (ERβA) and found low levels of cytochrome c and high levels of anti-apoptotic Bcl2 protein [27].

Another study done by Skavdahl et al. (2005) studied the role of E2-β in cardiac hypertrophy [28]. Upon inducing stress via TAC, they observed that mice with genotype of +/-E2-α showed the same response to stress as WT females mice. Also, females with genotype of +/-E2-β showed a significant increase in cardiac hypertrophy, thus, providing concrete data that ER-β plays a significant role in attenuating cardiac hypertrophy [28]. In the same study, Skavdahl et al. (2005) also elaborated on the importance of E2-β on the development of heart failure with reduced ejection fraction (HFrEF) [28]. By measuring the ratio of heart weight to body weight (HW/BW), they found that ERαKO male mice had the same HW/BW ratio compared to their WT counterparts. Whereas ERβKO mice showed a significant increase in HW/BW ratio [28].

Cardiac hypertrophy is a precursor to diastolic dysfunction, and E2 has been associated with preventing cardiac hypertrophy [29]. Pedram et al. (2008) demonstrated the protective effect of E2, in particular E2-β, on cardiac hypertrophy [29]. After infusing the animal models with ANG-II, which is a known potent vasoconstrictor, they found that animals lacking E2-β showed increased hypertrophy as compared to WT and E2-α KO, thus, indicating the important role of E2-β on cardiac hypertrophy, whereas E2-α did not seem to play a significant role in cardiac hypertrophy [29]. Table 3 summarizes the studies and their findings specific to ER-β.
Table 3: Cardioprotective role of estrogen receptor-β (ER-β)

| Author | Year | Receptor | Pathway/Marker | Cardiovascular pathology | Findings | Summary |
|--------|------|----------|----------------|--------------------------|----------|---------|
| Zhu et al. [24] | 2002 | E2-β | iNOS | HTN | E2-β deficient→↑vasoconstriction, ↓ iNPS production | Lack of E2-β plays role in vasoconstriction |
| Jazbutyte et al. [25] | 2008 | E2-β | 8β-VE2 | HTN | E2-β agonists→vasodilation | Administration of E2-β agonist improves vasodilation |
| Schubert et al. [27] | 2016 | E2-β | Cytochrome c, Bcl 2 | I/R injury | E2/ERβA→↑Bcl 2 and ↓cytochrome c, ↓caspase 9 | E2-β improves mitochondrial apoptosis |
| Skavdahl | 2005 | E2-β | Hypertrophy | Cardiac hypertrophy | HFrEF | E2-β plays a significant role in cardiac hypertrophy E2-β has beneficial role in heart failure with reduced ejection fraction |
| Pedram et al. [29] | 2008 | E2-β | Cardiac hypertrophy | ANG-II→↑hypertrophy in ERβKO ANG-II→decreased hypertrophy in WT and E2αKO | E2-β but not E2-α is cardioprotective against hypertrophy |

GPER

Traditionally, it was thought that estrogen exerts its cellular response only through nuclear receptors, E-α and E-β. However, recently a third kind of ER, GPER, has been found located in the endoplasmic reticulum that binds specifically to estrogen to produce nongenomic effects of estrogen [30]. Fredette et al. (2017) studied the involvement of GPER in the production of vasodilatory NO in human endothelial cells. After treating endothelial cells with non-selective ER, the study found a five-fold increase in the production of NO relative to basal NO [31]. Furthermore, treatment with G-1, a selective GPER agonist constituted 73% of NO production by E2 [31]. In addition, treatment with a G-1 selective antagonist reduced the NO production by 58%. The study also found that the activation of GPER led to the production of endothelial nitric oxide synthase (eNOS) which in turn activated a cascade of signaling pathways. eNOS activation by GPER involves PI3/Akt and ERK1/2 pathways, whereas the vasodilatory response involves s-Src/EGFR pathways [31]. Since estrogen is found to be protective against atherosclerosis, Meyer et al. (2014) studied the role of GPER in the progression of atherosclerosis [32]. In their G-protein coupled estrogen receptor knock-out (GPERKO) mouse model, they found that there was decreased production of vasodilatory NO and increased production of LDL, which led to the progression of atherosclerosis [32]. In another study, Deschamps et al. (2009) studied the cardioprotective role of GPER in I/R injury [33]. They found that the acute activation of GPER with G-1 was directly responsible for the activation of the PI3K/Akt pathway, which has cardioprotective properties [33]. To further delve into the mechanism of cardioprotection against I/R by GPER, Bopassa et al. (2010) designed an experimental study where they studied the G-1 induced cellular response in isolated mice hearts using the Langendorff technique [34]. Under stress, there was an increased calcium influx which caused an increased mitochondrial permeability transition pore (mPTP) opening. When treated with G-1, there was a decreased infarct size, improved cardiac function, and above all, decreased mPTP [34]. They also observed an increase in phosphorylation of Erk which led to the conclusion that the cardioprotective role of GPER is mediated through the Erk pathway. To further illustrate the role of Erk, they treated cardiac myocytes with PD (Erk inhibitor) which abolished the cardioprotective effect of G-1 [34]. Kang et al. (2012) studied the role of GPER in heart failure [35]. They induced heart failure in Sprague-Dawley rats with isoproterenol (ISO) and found a decrease in cardiac function, increase in fibrosis, increase in brain natriuretic peptide (BNP), and decrease in phosphorylated Akt in the OVX+ISO group, which was reversed in G-1 treated mice [35].

Table 4 provides the summary of the above-mentioned studies elucidating the specific cardioprotective role of GPER.
Table 4: Cardioprotective role of GPER

| Author          | Year | Receptor | Pathway/Marker | Cardiac pathology | Findings                                                                 | Summary/Conclusions                                                                 |
|-----------------|------|----------|----------------|-------------------|--------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Fredette et al. | 2017 | GPER     | eNOS           | HTN               | G-1→ ↑ eNOS→ ↑ c-Src,ERK1/2, GPER, PI3K/Akt→ ↑ NO production→ ↑ vasodilation→ ↓ Hypertension | GPER plays a vital role in NO production, thereby, decreasing HTN                   |
| Meyer et al.    | 2014 | GPER     | Atherosclerosis|                   | GPERKO→ ↓ NO production, ↑ LDL production, ↑ inflammation               | GPER plays a major role in progression of atherosclerosis                           |
| Deschamps et al.| 2009 | GPER     | Sprague-Dawley rat | Akt, ERK1/2, PI3K | ↓ infarct size, ↓ postischemic contractile dysfunction                    | Akt and ERK 1/2 pathways are protective; PI3K reverses the protection               |
| Bopassa et al.  | 2010 | GPER     | mPTP           | I/R               | G-1 → ↓ mPTP, ↓ infarct size, ↑ Erk → ↓ cell death                       | GPER protects against ischemia/reperfusion injury                                   |
| Kang et al.     | 2012 | GPER     | Heart failure  |                   | ISO→ ↓ ejection fraction, G-1→ ↑ ejection fraction                      | GPER improves ejection fraction                                                   |

Conclusions

TC is a reversible cardiomyopathy that impacts men and postmenopausal women more than premenopausal women. Estrogen seems to have a cardioprotective role in cardiomyopathies with a complex mechanism of action. The purpose of this article was to have a thorough understanding of this novel pathology. The studies mentioned in this article present us with strong pieces of evidence towards the cardioprotective role of estrogen with a positive impact on infarct size, cardiac hypertrophy, heart failure, etc. A major limitation of this article is that all the studies included in this review are animal based, thus, there is a need to develop human studies to extrapolate these findings. Although estrogen replacement therapy has been known to be beneficial against vaginal atrophy and osteoporosis, a significant side effect of estrogen supplement treatment is the development of a hypercoagulable state resulting in deep vein thrombosis and potentially pulmonary embolism. Therefore, we recommend future studies focus on an estrogen regimen that would be beneficial to both sexes. The most prevalent theory about the mechanism of TC is that elevated levels of catecholamines lead to a hyperadrenergic state. However, our research could not find an article linking estrogen and the hyperadrenergic state of catecholamines. In addition, we strongly recommend including estrogen levels as part of the initial blood work for patients presenting with signs and symptoms of cardiac pathology.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Amin HZ, Amin LZ, Pradipta A: Takotsubo cardiomyopathy: a brief review. J Med Life. 2020, 13:5-7. 10.25122/jml-2018-0067
2. Brinjikji W, El-Sayed AM, Salka S: In-hospital mortality among patients with takotsubo cardiomyopathy: a study of the National Inpatient Sample 2008 to 2009. Am Heart J. 2012, 164:215-21. 10.1016/j.ahj.2012.04.010
3. Stiermaier T, Moeller C, Oehler K, et al.: Long-term excess mortality in takotsubo cardiomyopathy: predictors, causes and clinical consequences. Eur J Heart Fail. 2016, 18:650-6. 10.1002/ejhf.494
4. Medina de Chazal H, Del Buono MG, Keyser-Marcus L, Ma L, Moeller FG, Berrocal D, Abbate A: Stress cardiomyopathy diagnosis and treatment: JACC state-of-the-art review. J Am Coll Cardiol. 2018, 72:1955-71. 10.1016/j.jacc.2018.07.072
5. Y-Hassan S, Tornvall P: Epidemiology, pathogenesis, and management of takotsubo syndrome. Clin Auton Res. 2018, 28:53-65. 10.1007/s10286-017-0465-2
6. Wittstein IS, Thiemann DR, Lima JA, et al.: Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med. 2005, 352:539-48. 10.1056/NEJMoa042046
7. Ghadri JR, Wittstein IS, Prasad A, et al.: International expert consensus document on takotsubo syndrome (Part II): clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J. 2018, 39:2032-46. 10.1093/eurheartj/ehy076
8. Ostadal B, Ostadal P: Sex-based differences in cardiac ischaemic injury and protection: therapeutic implications. Br J Pharmacol. 2014, 171:541-54. 10.1111/bph.12270
9. Ostadal B, Procházková J, Pelouch V, Urbanová D, Widimský J: Comparison of cardiopulmonary responses of male and female rats to intermittent high altitude hypoxia. Physiol Bohemoslov. 1984, 33:129-38.
10. Deschamps AM, Murphy E, Sun J: Estrogen receptor activation and cardioprotection in ischemia reperfusion injury. Trends Cardiovasc Med. 2010, 20:73-8. 10.1016/j.tcm.2010.05.001
11. Ueyama T, Ishikura F, Matsuda A, et al.: Chronic estrogen supplementation following ovariectomy improves the emotional stress-induced cardiovascular responses by indirect action on the nervous system and by direct action on the heart. Circ J. 2007, 71:565-73. 10.1253/circj.71.565
12. Booth EA, Obeid NR, Lucchesi BR: Activation of estrogen receptor-β protects the in vivo rabbit heart from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2005, 289:H2039-47. 10.1152/ajpheart.00479.2005
13. Pelzer T, Loza PA, Hu K, et al.: Increased mortality and aggravation of heart failure in estrogen receptor-β knockout mice after myocardial infarction. Circulation. 2005, 111:1492-98. 10.1161/CIRCULATIONAHA.105.555149
14. Wang M, Smith K, Yu Q, Miller G, Singh K, Sen CK: Mitochondrial connexin 43 in sex-dependent myocardial responses and estrogen-mediated cardiac protection following acute ischemia/reperfusion injury. Basic Res Cardiol. 2019, 115:1. 10.1007/s00395-019-0759-5
15. Satoh M, Matter CM, Ogita H, Takeshita K, Wang CY, Dorn II GW, Liao JK: Inhibition of apoptosis-regulated signalling kinase-1 and prevention of congestive heart failure by estrogen. Circulation. 2007, 115:3197-204. 10.1161/CIRCULATIONAHA.106.657981
16. Zhang Z, Xiang L, Zhao L, Jiao H, Wang Z, Li Y, Chen Y: The protective effect of Er-Xian decoction against myocardial injury in menopausal rat model. BMC Complement Altern Med. 2018, 18, 1245. 10.1186/s12906-018-2511-9
17. Booth EA, Lucchesi BR: Medroxyprogesterone acetate prevents the cardioprotective and anti-inflammatory effects of 17β-estradiol in an in vivo model of myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2007, 293:H1408-15. 10.1152/ajpheart.00995.2006
18. Xu Y, Armstrong SJ, Arenas IA, Pehowich DJ, Davidge ST: Cardioprotection by chronic estrogen or superoxide dismutase mimetic treatment in the aged female rat. Am J Physiol Heart Circ Physiol. 2004, 287:H165-71. 10.1152/ajpheart.00357.2004
19. Luo T, Liu H, Kim JK: Estrogen protects the female heart from ischemia/reperfusion injury through manganese superoxide dismutase phosphorylation by mitochondrial p38 at threonine 79 and serine 106. PLoS One. 2016, 11:e0167761. 10.1371/journal.pone.0167761
20. Xue B, Pamidimukkala J, Luhahn DB, Hay M: Estrogen receptor-α mediates estrogen protection from angiotensin II-induced hypertension in conscious female mice. Am J Physiol Heart Circ Physiol. 2007, 292:H1770-6. 10.1152/ajpheart.00101.2005
21. Wang M, Crisostomo P, Wairimu GM, Meldrum DR: Estrogen receptor-α mediates acute myocardial protection in females. Am J Physiol Heart Circ Physiol. 2006, 290:H2204-9. 10.1152/ajpheart.00129.2005
22. Ozaki K, Okubo T, Tanaka K, et al.: Manifestation of latent left ventricular outflow tract obstruction in the acute phase of takotsubo cardiomyopathy. Intern Med. 2016, 55:3413-20. 10.2169/internalmedicine.55.7119
23. Westphal C, Schubert C, Prelle K, Penkalla A, Fliegner D, Petrov G, Regitz-Zagrosek V: Estrogen protects the female heart from ischemia/reperfusion injury through manganese superoxide dismutase mimetic treatment in the aged female rat. Am J Physiol Heart Circ Physiol. 2004, 287:H165-71. 10.1152/ajpheart.00357.2004
24. Luo T, Liu H, Kim JK: Estrogen protects the female heart from ischemia/reperfusion injury through manganese superoxide dismutase mimetic phosphorylation by mitochondrial p38β at threonine 79 and serine 106. PLoS One. 2012, 7:e50802. 10.1371/journal.pone.0050802
25. Zhu Y, Biam Z, Lu P, et al.: Abnormal vascular function and hypertension in mice deficient in estrogen receptor β. Science. 2002, 295:505-8. 10.1126/science.1065250
26. Jazbutyte V, Arias-Loza PA, Hu K, et al.: Ligand-dependent activation of ERβ lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats. Cardiovasc Res. 2008, 77:774-81. 10.1093/cvr/cvm081
27. Borutaite V, Tokeikis A, Brown GC: In the eye of the storm: mitochondrial damage during heart and brain ischaemia. FEBS Lett. 2015, 580:4999-5014. 10.1111/febs.13235
28. Schubert C, Raparelli V, Westphal C, Dworatzek E, Petrov G, Kararigas G, Regitz-Zagrosek V: Estrogen receptor-α mediates acute myocardial protection in females. Am J Physiol Heart Circ Physiol. 2007, 293:H1204-9. 10.1152/ajpheart.00129.2005
29. Skavdahl M, Steenbergen C, Clark J, et al.: Estrogen receptor-β mediates male-female differences in the development of pressure overload hypertrophy. Am J Physiol Heart Circ Physiol. 2005, 288:H1466-76. 10.1152/ajpheart.00723.2004
30. Pedram A, Razandi M, Luhahn D, Liu J, Vannan M, Levin ER: Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-β to inhibit calcineurin. Endocrinology. 2008, 149:5361-9. 10.1210/en.2008-0135
31. Revankar CM, Cinimo DF, Sklar LA, Arterburn JB, Prossnitz ER: A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005, 307:1625-30. 10.1126/science.1100945
32. Fededte NC, Meyer MB, Prossnitz ER: Role of GPER in estrogen-dependent nitric oxide formation and vasodilation. J Steroid Biochem Mol Biol. 2018, 176:499-5014. 10.1016/j.jsbmb.2017.05.006
33. Meyer MB, Fededte NC, Howard TA, et al.: G protein-coupled estrogen receptor protects from atherosclerosis. Sci Rep. 2014, 4:7564. 10.1038/srep07564
34. Deschamps AM, Murphy E: Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol. 2009, 297:H1806-13. 10.1152/ajpheart.00283.2009
35. Bopassa JC, Eghball M, Torro L, Stefani E: A novel estrogen receptor GPER inhibits mitochondrial...
permeability transition pore opening and protects the heart against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2010, 298:H16-23. 10.1152/ajpheart.00588.2009

35. Kang S, Liu Y, Sun D, et al.: Chronic activation of the G protein-coupled receptor 30 with agonist G-1 attenuates heart failure. PLoS One. 2012, 7:e48185. 10.1371/journal.pone.0048185